Claims
- 1. A method for preventing or reducing platelet loss during extracorporeal circulation, in a mammalian species, which comprises administering to a mammalian species in need of such treatment an effective amount of a thromboxane A.sub.2 receptor antagonist alone or with an effective amount of prostacyclin and/or a prostacyclin mimic, said thromboxane A.sub.2 receptor antagonist being a 7-oxabicycloheptane or a 7-oxabicycloheptane derivative.
- 2. The method as defined in claim 1 wherein the thromboxane A.sub.2 antagonist is administered alone.
- 3. The method as defined in claim 1 wherein the thromboxane A.sub.2 antagonist is administered with prostacyclin and/or a prostacyclin mimic.
- 4. The method as defined in claim 1 wherein the thromboxane A.sub.2 antagonist is employed in a weight ratio to prostacyclin and/or a prostacyclin mimic of within the range of from about 2:1 to about 2000:1.
- 5. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist alone or with prostacyclin and/or a prostacyclin mimic is administered systemically.
- 6. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist alone or with prostacyclin and/or a prostacyclin mimic is administered intravenously.
- 7. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist alone or with prostacyclin and/or a prostacyclin mimic is administered during extracorporeal circulation.
- 8. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist alone or with prostacyclin and/or a prostacyclin mimic is administered prior to extracorporeal circulation.
- 9. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist when used with prostacyclin or a prostacyclin mimic is a 7-oxabicycloheptane.
- 10. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist is a 7-oxabicycloheptane substituted amino-prostaglandin analog.
- 11. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist is a 7-oxabicycloheptane substituted diamide prostaglandin analog.
- 12. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist is a phenoxyalkyl carboxylic acid.
- 13. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist is a sulfonamidophenyl carboxylic acid.
- 14. The method as defined in claim 1 wherein the thromoboxane A.sub.2 receptor antagonist is an arylthioalkylphenyl carboxylic acid.
- 15. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist is [1S-[1.alpha.,2.beta.(5Z),3.beta.(1E,3R,4S),4.alpha.]]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
- 16. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist has the name [1S-[1.beta.,2.alpha.(5Z),3.alpha.,4.beta.]]-7-[3-[[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or the corresponding tetrazole.
- 17. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist has the name [1S-[1<.alpha.,2<.beta.(Z),3<.beta.,4<.alpha.]]-7-[3-[[[[(4-cyclohexyl-1-oxobutyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptanoic acid.
- 18. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist has the name [1S-[1.alpha.,2.beta.(5Z),3.beta.,4.alpha.]]-7-[3-[[2-(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
- 19. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist has the name 4-(3-((4-chlorophenyl)sulfonyl)propyl)benzene acetic acid.
- 20. The method as defined in claim 1 wherein the thromboxane A.sub.2 receptor antagonist has the name or 4-[2-(benzenesulfamido)ethyl]phenoxyacetic acid or 4-[2-(4-chlorobenzenesulfonamido)ethyl]phenylacetic acid.
Parent Case Info
This is a division of application Ser. No. 165,065, filed Mar. 7, 1988.
Divisions (1)
|
Number |
Date |
Country |
Parent |
165065 |
Mar 1988 |
|